CLOTTAFACT Trademark

Trademark Overview

On Thursday, August 11, 2022, a trademark application was filed for CLOTTAFACT with the United States Patent and Trademark Office. The USPTO has given the CLOTTAFACT trademark a serial number of 79348828. The federal status of this trademark filing is REGISTERED as of Tuesday, March 5, 2024. This trademark is owned by Laboratoire Français du Fractionnement et des Biotechnologies. The CLOTTAFACT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products and preparations for the prevention, treatment and control of bleeding episodes; blood protein arrays of natural or transgenic, synthetic or semi-synthetic origin for medical diagnosis purposes
clottafact

General Information

Serial Number79348828
Word MarkCLOTTAFACT
Filing DateThursday, August 11, 2022
Status700 - REGISTERED
Status DateTuesday, March 5, 2024
Registration Number7318153
Registration DateTuesday, March 5, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements

Goods and ServicesPharmaceutical products and preparations for the prevention, treatment and control of bleeding episodes; blood protein arrays of natural or transgenic, synthetic or semi-synthetic origin for medical diagnosis purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 2, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLaboratoire Français du Fractionnement et des Biotechnologies
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressFR
Party NameLaboratoire Français du Fractionnement et des Biotechnologies
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFR
Party NameLaboratoire Français du Fractionnement et des Biotechnologies
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFR

Trademark Events

Event DateEvent Description
Thursday, September 1, 2022SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Friday, September 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 6, 2022APPLICATION FILING RECEIPT MAILED
Wednesday, May 31, 2023ASSIGNED TO EXAMINER
Thursday, June 1, 2023NON-FINAL ACTION WRITTEN
Friday, June 2, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, July 8, 2023REFUSAL PROCESSED BY MPU
Sunday, July 9, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sunday, August 6, 2023REFUSAL PROCESSED BY IB
Wednesday, November 15, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 15, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 15, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 15, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 29, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 29, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 2, 2024NOTIFICATION PROCESSED BY IB
Monday, February 26, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Wednesday, February 7, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 7, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, March 5, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, March 5, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 7, 2024NEW REPRESENTATIVE AT IB RECEIVED
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

Related Keywords

clottafact synthetic transgenic natural semi origin purposes diagnosis medical arrays protein